Notice for moxetumomab pasudotox (AstraZeneca Pty Ltd)
Active ingredients
moxetumomab pasudotox
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Powder for injection
Indication
Treatment of hairy cell leukaemia
Therapeutic area
Haematology